Idenix Pharmaceuticals (IDIX)

[gofishmarko]

>>> In other words, McMinn does not depict any scenario in which the two drugs are fully additive or more than fully additive, which is the usual meaning of synergy. <<<

Yes, and it makes me suspicious of the entire analysis. I think she had a good basis for her argument - the replicon studies which showed antagonism between NM283 and riba - but she went too far with it in her 'scenarios'.

#3 , which was based on no antagonism , should have assumed at least a modest benefit to NM283 addition to SOC. Instead it showed a detriment.

And in #4 , just to cover her butt re: Murphy's Law , she should have assumed a significant , true synergism.

That way ,if the trial results are unexpectedly good , she would be covered. As it is now , if the combo shines , her cred will be shot.

What a shame that would be , eh ?